News from the FDA/CDC
News from the FDA/CDC
FDA approves first drug that protects against chemo-induced myelosuppression
News
Some COVID-19 vaccine reactions could be pseudoallergic, experts say
News from the FDA/CDC
Cemiplimab approved for locally advanced, metastatic basal cell carcinoma
The approval is based on phase 2 trial results.
News from the FDA/CDC
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
Completed safety clinical trial shows occurrence of heart-related events and cancer in RA patients taking the Janus kinase inhibitor is higher...
News from the FDA/CDC
FDA grants MET inhibitor tepotinib accelerated approval for NSCLC
Tepotinib is the first once-daily oral MET inhibitor approved for this patient population.
News from the FDA/CDC
CDC panel: No COVID-19 vaccine safety surprises
News
Anaphylaxis cases after COVID-19 vaccine rising but still rare: CDC
News from the FDA/CDC
CDC issues COVID-19 vaccine guidance for underlying conditions
The CDC guidance had specific information for people with ...
News from the FDA/CDC
Moderna’s COVID-19 vaccine deemed ‘highly effective,’ but further studies needed
The primary safety endpoint was to characterize the safety of the vaccine following one or two doses.
News from the FDA/CDC
FDA OKs osimertinib as first adjuvant drug for NSCLC
The approval is based on results of the ADAURA trial.
News from the FDA/CDC
FDA OKs first oral hormone therapy for advanced prostate cancer
Relugolix is an oral form of androgen deprivation therapy.